CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|Switzerland
$48.44
-0.71 (-1.44%)
Tangible Book
$20.04
Upcoming Data Readouts (3)
Jun 2027
Est. completion
P1Cardiovascular
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172n=90
Jan 2030
Est. completion
P1P2B-cell Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742n=120
Dec 2031
Est. completion
P1SLE (Systemic Lupus)
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542n=80
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
May 2026
P3
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649May 2026
P3
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195